

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

**Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)**

Filed by the Registrant
Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material under §240.14a-12



DECIPHERA PHARMACEUTICALS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
 Fee paid previously with preliminary materials.
 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



P.O. BOX 8016, CARY, NC 27512-8903

Your vote matters!



Scan QR for digital voting

Deciphera Pharmaceuticals, Inc. Annual Meeting of Stockholders

Thursday, June 20, 2024 8:30 AM, Eastern Time

Annual Meeting to be held virtually over the Internet - please visit www.proxydocs.com/DCPH for more details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/DCPH

For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/DCPH

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 10, 2024.

SEE REVERSE FOR FULL AGENDA

Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-K

Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 20, 2024 For Stockholders of record as of April 23, 2024

To order paper materials, use one of the following methods.



Internet:
www.investorelections.com/DCPH



Call:
1-866-648-8133



Email:
paper@investorelections.com

* If requesting materials by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting materials.

Your control number

Have the 12 digit control number located in the box above available when you access the website and follow the instructions.



**THE BOARD OF DIRECTORS RECOMMENDS A VOTE:
FOR ON PROPOSALS 1, 2, 3, 4, 5 AND 6**

PROPOSAL

1. To elect three Class I directors, as nominated by the Board of Directors, to hold office until the 2027 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation, or removal;
 - 1.01 James A. Bristol, Ph.D.
 - 1.02 Frank S. Friedman
 - 1.03 Ron Squarer
2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice;
3. To ratify the appointment of PricewaterhouseCoopers LLP as Deciphera Pharmaceuticals, Inc.'s independent registered public accounting firm for the year ending December 31, 2024;
4. To approve an amendment to the Amended and Restated Certificate of Incorporation of Deciphera Pharmaceuticals, Inc. ("Certificate of Incorporation") to increase the number of authorized shares of our common stock, \$0.01 par value per share, from 125,000,000 to 250,000,000;
5. To approve an amendment to the Certificate of Incorporation to permit limitation of liability of certain Deciphera Pharmaceuticals, Inc. officers as and to the extent provided and permitted by Section 102(b)(7) of the General Corporation Law of Delaware;
6. To approve the adjournment of the 2024 Annual Meeting of Stockholders to the extent there are insufficient votes at the Annual Meeting to approve the proposals mentioned in items 4 and 5 above; and
7. To transact such other business as may properly come before the meeting and at any adjournments or postponements thereof.